{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:59:33Z","timestamp":1789419573543,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,29]]},"DOI":"10.7759\/cureus.86959","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T12:32:08Z","timestamp":1751200328000},"source":"Crossref","is-referenced-by-count":4,"title":["Serum Galectin-3 and Risk Stratification in Chronic Heart Failure: A Systematic Review of Mortality Outcomes"],"prefix":"10.7759","author":[{"given":"Saad","family":"Sulaiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan Abdulhaleem","family":"Mohamed Khalafallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Elbadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tagwa Mohamed","family":"Abuelgasim Mohamedsalih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manahil Abdalla","family":"Mohamed Salih Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Mohammed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v17.i4.104717","article-title":"Emerging risk factors for heart failure in younger populations: a growing public health concern","volume":"17","author":"Parizad R","year":"2025","unstructured":"Parizad R, Batta A, Hatwal J, Taban-Sadeghi M, Mohan B. Emerging risk factors for heart failure in younger populations: a growing public health concern. World J Cardiol. 2025, 17:104717. 10.4330\/wjc.v17.i4.104717","journal-title":"World J Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713111","article-title":"The role of galectin-3 in heart failure\u2014the diagnostic, prognostic and therapeutic potential\u2014where do we stand?","volume":"24","author":"Zaborska B","year":"2023","unstructured":"Zaborska B, Sikora-Fr\u0105c M, Smar\u017c K, Pilichowska-Paszkiet E, Budaj A, Sitkiewicz D, Sygitowicz G. The role of galectin-3 in heart failure\u2014the diagnostic, prognostic and therapeutic potential\u2014where do we stand?. Int J Mol Sci. 2023, 24:13111. 10.3390\/ijms241713111","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091277","article-title":"Galectin-3: a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology","volume":"10","author":"Hara A","year":"2020","unstructured":"Hara A, Niwa M, Kanayama T, et al.. Galectin-3: a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules. 2020, 10:1277. 10.3390\/biom10091277","journal-title":"Biomolecules"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1304735","article-title":"Unraveling the role of galectin-3 in cardiac pathology and physiology","volume":"14","author":"Seropian IM","year":"2023","unstructured":"Seropian IM, Cassaglia P, Miksztowicz V, Gonz\u00e1lez GE. Unraveling the role of galectin-3 in cardiac pathology and physiology. Front Physiol. 2023, 14:1304735. 10.3389\/fphys.2023.1304735","journal-title":"Front Physiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.748875","article-title":"The diagnostic and prognostic value of plasma galectin 3 in HFrEF related to the etiology of heart failure","volume":"8","author":"Lu Q","year":"2021","unstructured":"Lu Q, Zhang RC, Chen SP, et al.. The diagnostic and prognostic value of plasma galectin 3 in HFrEF related to the etiology of heart failure. Front Cardiovasc Med. 2021, 8:748875. 10.3389\/fcvm.2021.748875","journal-title":"Front Cardiovasc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04266-6","article-title":"Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model","volume":"79","author":"Vlachou F","year":"2022","unstructured":"Vlachou F, Varela A, Stathopoulou K, et al.. Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model. Cell Mol Life Sci. 2022, 79:250. 10.1007\/s00018-022-04266-6","journal-title":"Cell Mol Life Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111066","article-title":"Research progress on the role of Gal-3 in cardio\/cerebrovascular diseases","volume":"133","author":"Cao ZQ","year":"2021","unstructured":"Cao ZQ, Yu X, Leng P. Research progress on the role of Gal-3 in cardio\/cerebrovascular diseases. Biomed Pharmacother. 2021, 133:111066. 10.1016\/j.biopha.2020.111066","journal-title":"Biomed Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.783707","article-title":"Prognostic value of serum galectin-3 in chronic heart failure: a meta-analysis","volume":"9","author":"Cheng Z","year":"2022","unstructured":"Cheng Z, Cai K, Xu C, Zhan Q, Xu X, Xu D, Zeng Q. Prognostic value of serum galectin-3 in chronic heart failure: a meta-analysis. Front Cardiovasc Med. 2022, 9:783707. 10.3389\/fcvm.2022.783707","journal-title":"Front Cardiovasc Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden JA","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013, 158:280-6. 10.7326\/0003-4819-158-4-201302190-00009","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF","volume":"73","author":"Zile MR","year":"2019","unstructured":"Zile MR, O'Meara E, Claggett B, et al.. Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019, 73:795-806. 10.1016\/j.jacc.2018.11.042","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.08.042","article-title":"Exploring collagen remodeling and regulation as prognosis biomarkers in stable heart failure","volume":"490","author":"Dupuy AM","year":"2019","unstructured":"Dupuy AM, Kuster N, Curinier C, et al.. Exploring collagen remodeling and regulation as prognosis biomarkers in stable heart failure. Clin Chim Acta. 2019, 490:167-71. 10.1016\/j.cca.2018.08.042","journal-title":"Clin Chim Acta"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000750","article-title":"The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure","volume":"5","author":"Binas D","year":"2018","unstructured":"Binas D, Daniel H, Richter A, Ruppert V, Schl\u00fcter KD, Schieffer B, Pankuweit S. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart. 2018, 5:e000750. 10.1136\/openhrt-2017-000750","journal-title":"Open Heart"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0470-x","article-title":"Impact of diabetes on the predictive value of heart failure biomarkers","volume":"15","author":"Alonso N","year":"2016","unstructured":"Alonso N, Lup\u00f3n J, Barallat J, et al.. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovasc Diabetol. 2016, 15:151. 10.1186\/s12933-016-0470-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.246850","article-title":"Interaction of galectin-3 concentrations with the treatment effects of \u03b2-blockers and RAS blockade in patients with systolic heart failure: a derivation-validation study from TIME-CHF and GISSI-HF","volume":"62","author":"Sanders-van Wijk S","year":"2016","unstructured":"Sanders-van Wijk S, Masson S, Milani V, et al.. Interaction of galectin-3 concentrations with the treatment effects of \u03b2-blockers and RAS blockade in patients with systolic heart failure: a derivation-validation study from TIME-CHF and GISSI-HF. Clin Chem. 2016, 62:605-16. 10.1373\/clinchem.2015.246850","journal-title":"Clin Chem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119160","article-title":"The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists","volume":"10","author":"Koukoui F","year":"2015","unstructured":"Koukoui F, Desmoulin F, Galinier M, et al.. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. PLoS One. 2015, 10:e0119160. 10.1371\/journal.pone.0119160","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis A","year":"2014","unstructured":"Bayes-Genis A, de Antonio M, Vila J, et al.. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014, 63:158-66. 10.1016\/j.jacc.2013.07.087","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.14.31","article-title":"Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure","volume":"8","author":"Jungbauer CG","year":"2014","unstructured":"Jungbauer CG, Riedlinger J, Block D, et al.. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark Med. 2014, 8:777-89. 10.2217\/bmm.14.31","journal-title":"Biomark Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0500-y","article-title":"Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure","volume":"102","author":"Lok DJ","year":"2013","unstructured":"Lok DJ, Lok SI, Bruggink-Andr\u00e9 de la Porte PW, et al.. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013, 102:103-10. 10.1007\/s00392-012-0500-y","journal-title":"Clin Res Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.08.021","article-title":"The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"164","author":"Gullestad L","year":"2012","unstructured":"Gullestad L, Ueland T, Kjekshus J, et al.. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012, 164:878-83. 10.1016\/j.ahj.2012.08.021","journal-title":"Am Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.05.081","article-title":"Galectin-3 in heart failure: high levels are associated with all-cause mortality","volume":"150","author":"Ueland T","year":"2011","unstructured":"Ueland T, Aukrust P, Broch K, Aakhus S, Sk\u00e5rdal R, Muntendam P, Gullestad L. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol. 2011, 150:361-4. 10.1016\/j.ijcard.2011.05.081","journal-title":"Int J Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang WH","year":"2011","unstructured":"Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011, 108:385-90. 10.1016\/j.amjcard.2011.03.056","journal-title":"Am J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction","volume":"3","author":"de Boer RA","year":"2018","unstructured":"de Boer RA, Nayor M, deFilippi CR, et al.. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018, 3:215-24. 10.1001\/jamacardio.2017.4987","journal-title":"JAMA Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study","volume":"5","author":"Felker GM","year":"2012","unstructured":"Felker GM, Fiuzat M, Shaw LK, et al.. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012, 5:72-8. 10.1161\/CIRCHEARTFAILURE.111.963637","journal-title":"Circ Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson NC","year":"2006","unstructured":"Henderson NC, Mackinnon AC, Farnworth SL, et al.. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006, 103:5060-5. 10.1073\/pnas.0511167103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2013.10.010","article-title":"Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy","volume":"19","author":"Bell SP","year":"2013","unstructured":"Bell SP, Adkisson DW, Ooi H, Sawyer DB, Lawson MA, Kronenberg MW. Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy. J Card Fail. 2013, 19:802-10. 10.1016\/j.cardfail.2013.10.010","journal-title":"J Card Fail"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus J","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V, et al.. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007, 357:2248-61. 10.1056\/NEJMoa0706201","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.843979","article-title":"Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia\/reperfusion through protein-kinase G-dependent generation of hydrogen sulfide","volume":"120","author":"Salloum FN","year":"2009","unstructured":"Salloum FN, Chau VQ, Hoke NN, et al.. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia\/reperfusion through protein-kinase G-dependent generation of hydrogen sulfide. Circulation. 2009, 120:S31-6. 10.1161\/CIRCULATIONAHA.108.843979","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma UC","year":"2004","unstructured":"Sharma UC, Pokharel S, van Brakel TJ, et al.. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004, 110:3121-8. 10.1161\/01.CIR.0000147181.65298.4D","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.06.025","article-title":"Galectin-3 and post-myocardial infarction cardiac remodeling","volume":"763","author":"Meijers WC","year":"2015","unstructured":"Meijers WC, van der Velde AR, Pascual-Figal DA, de Boer RA. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015, 763:115-21. 10.1016\/j.ejphar.2015.06.025","journal-title":"Eur J Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky B","year":"2011","unstructured":"Ky B, French B, McCloskey K, et al.. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011, 4:180-7. 10.1161\/CIRCHEARTFAILURE.110.958223","journal-title":"Circ Heart Fail"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58070952","article-title":"Biomarkers for Alzheimer\u2019s disease: context of use, qualification, and roadmap for clinical implementation","volume":"58","author":"Cummings J","year":"2022","unstructured":"Cummings J, Kinney J. Biomarkers for Alzheimer\u2019s disease: context of use, qualification, and roadmap for clinical implementation. Medicina (Kaunas). 2022, 58:952. 10.3390\/medicina58070952","journal-title":"Medicina (Kaunas)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi631","article-title":"NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP study","volume":"27","author":"Januzzi JL","year":"2006","unstructured":"Januzzi JL, van Kimmenade R, Lainchbury J, et al.. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP study. Eur Heart J. 2006, 27:330-7. 10.1093\/eurheartj\/ehi631","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/690205","article-title":"Prognostic value of galectin-3 in patients with heart failure","volume":"2015","author":"Bo\u0161njak I","year":"2015","unstructured":"Bo\u0161njak I, Selthofer-Relati\u0107 K, V\u010dev A. Prognostic value of galectin-3 in patients with heart failure. Dis Markers. 2015, 2015:690205. 10.1155\/2015\/690205","journal-title":"Dis Markers"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383784-serum-galectin-3-and-risk-stratification-in-chronic-heart-failure-a-systematic-review-of-mortality-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T12:32:08Z","timestamp":1751200328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383784-serum-galectin-3-and-risk-stratification-in-chronic-heart-failure-a-systematic-review-of-mortality-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.86959","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}